Nuvation Bio expands Phase 3 SIGMA study of safusidenib to six European countries for brain cancer treatment

Nuvation Bio announced the expansion of its pivotal Phase 3 SIGMA study of safusidenib, an investigational drug targeting mutant IDH1 gliomas, to include new sites in the UK, France, Sweden, Germany, Italy, and Spain. This expansion broadens the study's global reach beyond the US, Australia, China, Canada, and Japan, aiming to enroll around 300 patients with high-risk IDH1-mutant astrocytoma and an exploratory cohort of 40 patients with grade 3 IDH1-mutant oligodendroglioma. Safusidenib is an oral, brain-penetrant inhibitor showing promise in delaying disease progression and improving outcomes in brain cancer patients. The study's primary endpoint is progression-free survival, and the FDA has granted safusidenib Fast Track Designation, highlighting its potential to address unmet medical needs in glioma treatment.

Nuvation Bio's stock (NUVB) is trading at USD 4.59 on Pluang as of Oct 29, 2026 19:12 WIB, holding steady with no change in the past day. This price is closer to its 52-week low of USD 4.05 than its high of USD 9.54, indicating the stock is currently valued near the lower end of its annual range. The market cap stands at $1.61 billion, reflecting its mid-size position in the health sector. The typical hold time of 13 days suggests moderate investor interest in this stock at present.